Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 May;15(5):401-8.
doi: 10.1089/dia.2013.0002. Epub 2013 Apr 9.

The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis

Collaborators
Randomized Controlled Trial

The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis

Diabetes Research in Children Network (DirecNet) Study Group et al. Diabetes Technol Ther. 2013 May.

Abstract

Background: This article describes our experience with inpatient hybrid closed-loop control (HCLC) initiated shortly after the diagnosis of type 1 diabetes in a randomized trial designed to assess the effectiveness of inpatient HCLC followed by outpatient sensor-augmented pump (SAP) therapy on the preservation of β-cell function.

Subjects and methods: Forty-eight individuals with newly diagnosed type 1 diabetes and positive pancreatic autoantibodies (7.8-37.7 years old) received inpatient HCLC therapy for up to 93 h, initiated within 7 days of diagnosis.

Results: On initiation of HCLC, mean glucose concentration was 240±100 mg/dL. During the first day of HCLC, median of the participant's mean glucose concentrations fell rapidly to 146 mg/dL, a level of control that was sustained on Days 2 and 3 (138 mg/dL and 139 mg/dL, respectively). By Day 3, the median percentage of glucose values >250 and <60 mg/dL was <1%. During the first 2 weeks of SAP treatment at home, the median participant mean glucose level was 126 mg/dL (interquartile range, 117, 137 mg/dL), and the median percentage of values between 71 and 180 mg/dL was 85% (interquartile range, 80%, 90%).

Conclusions: Inpatient HCLC followed by outpatient SAP therapy can provide a safe and effective means to rapidly reverse glucose toxicity and establish near-normal glycemic control in patients with newly diagnosed type 1 diabetes.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Participant mean glucose values from a continuous glucose monitor worn prior to admission, during hybrid closed-loop (HCL) control, and 2 weeks following discharge (n=48). The bottom and top of each box denote the 25th and 75th percentiles, respectively, the line inside the box denotes the median, and the dot is the mean.
FIG. 2.
FIG. 2.
Distribution of percentage of continuous glucose monitor glucose values 71–180 mg/dL from a continuous glucose monitor worn prior to admission, during hybrid closed-loop (HCL) control, and 2 weeks following discharge (n=48). The bottom and top of each box denote the 25th and 75th percentiles, respectively, the line inside the box denotes the median, and the dot is the mean.

References

    1. Shah SC. Malone JI. Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med. 1989;320:550–554. - PubMed
    1. Kordonouri O. Pankowska E. Rami B. Kapellen T. Coutant R. Hartmann R. Lange K. Knip M. Danne T. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53:2487–2495. - PubMed
    1. Steffes MW. Sibley S. Jackson M. Thomas W. β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26:832–836. - PubMed
    1. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med. 1998;128:517–523. - PubMed
    1. Bergenstal RM. Tamborlane WV. Ahmann A. Buse JB. Dailey G. Davis SN. Joyce C. Peoples T. Perkins BA. Welsh JB. Willi SM. Wood MA the STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320. - PubMed

Publication types